Skarlos, P <br/><br/>
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Feb 2012 
 - 533-46 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-011-1730-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant<br/>Clinical Trials, Phase III as Topic<br/>Cluster Analysis<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Estrogen Receptor alpha--genetics<br/>Estrogen Receptor beta--genetics<br/>Female<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Immunohistochemistry<br/>Middle Aged<br/>Outcome Assessment, Health Care--methods<br/>Phenotype<br/>Prognosis<br/>Randomized Controlled Trials as Topic<br/>Receptor, ErbB-2--genetics<br/>Receptors, Estrogen--genetics<br/>Receptors, Progesterone--genetics<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Translational Research, Biomedical--methods<br/>Young Adult